Cureus . Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia

[tetano]

Cureus


. 2021 May 27;13(5):e15280.
doi: 10.7759/cureus.15280.
Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia


Alexander T Phan ¹ , Janet Gukasyan ¹ , Sarkis Arabian ² , Sharon Wang ³ , Michael M Neeki ⁴



Affiliations

• PMID: 34194882
• PMCID: PMC8235874
• DOI: 10.7759/cureus.15280

Abstract

Infection by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is known to have the highest mortality rate among the elderly and those with pre-existing medical conditions. Viral load has been directly correlated with increased risk of mortality in hospitalized patients. Once infected, symptoms first arise approximately six to seven days later followed by immunoglobulin M (IgM) antibodies appearing 8-12 days after onset of clinical symptoms. Recent studies have noted that the monoclonal antibody combination of casirivimab and imdevimab (REGN-COV2) effectively reduces viral load in infected seronegative non-hospitalized patients. However, research supporting the use of REGN-COV2 in an inpatient setting is limited. We present the case of a 45-year-old male with confirmed SARS-CoV-2 infection with moderate dyspnea and progressive worsening of his symptoms over a week period. The patient showed drastic improvement of his symptoms after a single low-dose regimen of REGN-COV2 infusion while admitted to the hospital and was subsequently discharged without further medical complications.

Keywords: casirivimab; coronavirus; covid-19; imdevimab; monoclonal antibodies; pneumonia.